A Structured Preapproval and Postapproval Comparative Study Design Framework to Generate Valid and Transparent Real‐World Evidence for Regulatory Decisions
暂无分享,去创建一个
[1] Richard F MacLehose,et al. Good practices for quantitative bias analysis. , 2014, International journal of epidemiology.
[2] Susan Rose,et al. International Ethical Guidelines for Epidemiological Studies By the Council for International Organizations of Medical Sciences (CIOMS) , 2009 .
[3] S. Schneeweiss,et al. Improving therapeutic effectiveness and safety through big healthcare data , 2016, Clinical pharmacology and therapeutics.
[4] David Martin,et al. Evaluating the Use of Nonrandomized Real‐World Data Analyses for Regulatory Decision Making , 2019, Clinical pharmacology and therapeutics.
[5] David M. Evans,et al. Collider scope: when selection bias can substantially influence observed associations , 2016, bioRxiv.
[6] R Platt,et al. Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision‐Making , 2016, Clinical pharmacology and therapeutics.
[7] N. Dreyer,et al. Considerations in characterizing real‐world data relevance and quality for regulatory purposes: A commentary , 2018, Pharmacoepidemiology and drug safety.
[8] R. D'Agostino,et al. The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics. , 2008, The Journal of clinical psychiatry.
[9] Tyler J. VanderWeele,et al. Sensitivity Analysis in Observational Research: Introducing the E-Value , 2017, Annals of Internal Medicine.
[10] S. Schwartz,et al. Toward a Clarification of the Taxonomy of “Bias” in Epidemiology Textbooks , 2015, Epidemiology.
[11] G. Bedogni. Applying Quantitative Bias Analysis to Epidemiologic Data , 2011 .
[12] Nancy A. Dreyer,et al. Advancing a Framework for Regulatory Use of Real-World Evidence , 2018, Therapeutic innovation & regulatory science.
[13] Canary Wharf,et al. The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) , 2012 .
[14] J. Lieberman,et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.
[15] J. Pearl. Causal diagrams for empirical research , 1995 .
[16] A. Fourrier-Réglat,et al. The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology (Revision 1, 2012, Revision 2, 2013, Revision 3, 2014)). , 2012 .
[17] Amy P. Abernethy,et al. Harnessing the Power of Real‐World Evidence (RWE): A Checklist to Ensure Regulatory‐Grade Data Quality , 2017, Clinical pharmacology and therapeutics.
[18] Miguel A Hernán,et al. With great data comes great responsibility: publishing comparative effectiveness research in epidemiology. , 2011, Epidemiology.
[19] R. Anziano,et al. A Randomized Evaluation of the Effects of Six Antipsychotic Agents on QTc, In the Absence and Presence of Metabolic Inhibition , 2004, Journal of clinical psychopharmacology.
[20] J. Kane,et al. Lessons learned in the conduct of a global, large simple trial of treatments indicated for schizophrenia. , 2013, Contemporary clinical trials.
[21] Sander Greenland,et al. Multiple‐bias modelling for analysis of observational data , 2005 .
[22] T. S. Stroup. What can large simple trials do for psychiatry? , 2011, The American journal of psychiatry.
[23] David Madigan,et al. Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR‐ISPE Special Task Force on real‐world evidence in health care decision making , 2017, Pharmacoepidemiology and drug safety.
[25] G. Shaw,et al. Maternal pesticide exposure from multiple sources and selected congenital anomalies. , 1999 .
[26] James M Robins,et al. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. , 2016, American journal of epidemiology.
[27] R. D'Agostino,et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). , 2011, The American journal of psychiatry.
[28] J. Pearl,et al. Causal diagrams for epidemiologic research. , 1999, Epidemiology.
[29] B. Klein,et al. Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors. , 2015, The journal of sexual medicine.
[30] T. Richardson. Single World Intervention Graphs ( SWIGs ) : A Unification of the Counterfactual and Graphical Approaches to Causality , 2013 .